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Abstract
The study is aimed at identifying the key aspects of the national pharmacopeial regulation of the circulation of 
biotechnological medicines in the Russian pharmaceutical market and at studying the range of major groups based 
on the analysis of restrictive lists. The systematic analysis of the new national State Pharmacopeia has resulted 
in the identification of the newly-introduced general pharmacopeia monographs on biotechnological medicines 
and their groups, establishing the monographs on specific items, and the generalization of the basic conditions for 
ensuring quality in production. The content analysis of the restrictive lists has made it possible to determine the vital 
and most important items by the main groups of biotechnological medicines.
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Introduction
Biotechnological medicines refer to biological 
medicines and occupy the most important place in 
modern healthcare.
Since 2014, the national state regulation 
of various aspects related to the circulation of the 
medicines in this group has been actively improved [1], 
[2], [3], [4], [5], [6].
The development of a common market for 
medicines within the framework of the Eurasian 
Economic Union is accompanied by the harmonization 
of interstate regulatory requirements, including the 
circulation of biological products [7], [8], [9], [10].
At the end of 2018, Russia approved the 14th 
edition of the State Pharmacopeia, which implements 
many new requirements for biotechnological preparations.
The annually approved list of vital and essential 
drugs and other restrictive lists provide priority health needs 
for the prevention and treatment of diseases. For subjects 
of the pharmaceutical market, information on updating the 
data of the lists, in which biological medicines occupy a 
prominent place, is always relevant and interesting.
Methods
Content analysis of the national Federal 
law on the circulation of medicines by the keywords 
“biotechnological medicines”, “biological medicines” 
and identification of regulatory frameworks for this 
group of medicines have been conducted.
System analysis of the new 14th edition of the 
State Pharmacopeia to establish general pharmacopeia 
monographs (hereinafter – GPM) and the monographs 
on biotechnological medicines, and determine novelty 
(Federal Electronic Medical Library femb.ru ›femb/
pharmacopea.php).
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Analysis of the newly introduced general 
pharmacopoeia monograph “Biotechnological medicines” 
and identification of the basic requirements for producers 
for the quality of the medicines in this group were made.
Analysis of the main groups of biotechnological 
medicines in the 14th edition of the State Pharmacopeia 
revealing the peculiarities of pharmacopeia regulation 
under the new general pharmacopeia monographs.
Up-to-date content analysis of the restrictive 
lists for 2019, identification of vital and essential 
drugs, the list of preferential provision drugs, and 
the medicines for twelve high-cost nosologies by 
groups of biotechnological medicines in new general 
pharmacopeia monographs.
Studying the results of the evaluation of the 
inclusion of medicines in the restrictive lists for 2020 on 
the official website of the Ministry of Health of Russia 
and determining the prospects for new biotechnological 
medicines.
Results
In the national legislation, the concept of 
“Biotechnological medicines” first appeared in 2015. 
Biotechnological medicines belong to one of four 
groups of biological medicines.
In general, biological medicines are the drugs 
whose active substance is produced or isolated from 
a biological source, with a combination of biological 
and physicochemical methods being necessary for 
determining their properties and quality.
The federal law on the circulation of medicines 
defines biotechnological medicines as the drugs 
produced using biotechnological processes and methods 
(including DNA recombinant technology, technology for 
the controlled expression of genes encoding biologically 
active proteins in prokaryotes and eukaryotes, including 
altered mammalian cells), hybridoma technology, and 
monoclonal antibodies method.
The order of the Ministry of Health of Russia 
No. 749 dated October 31, 2018, approved the general 
pharmacopeia monographs and the pharmacopeia 
monographs, and also established that they constituted 
the 14th edition of the new State Pharmacopeia.
The 14th edition of the State Pharmacopeia 
has introduced the general pharmacopeia monograph 
“Biotechnological medicines” (hereinafter referred to as 
the GPM.1.7.1.0011.18 “Biotechnological medicines”), 
as well as other general pharmacopeia monographs 
for certain groups of biotechnological preparations 
(hereinafter the BtM).
The BtM may contain proteins, peptides or 
derivatives of proteins and peptides, glycoproteins, 
live or inactivated microbes (bacteria, viruses), their 
antigens, antibodies to them, metabolites, and other 
biologically-sourced active substances (e.g., probiotics, 
bacteriophages, cytokines, monoclonal antibodies, 
recombinant proteins, etc.).
The BtM may include excipients of various 
purposes (stabilizers, sorbents, preservatives, fillers, etc.).
It is important to note that the general 
pharmacopeia monograph of the 14th edition of the 
State Pharmacopeia “Biotechnological Medicines” 
does not apply to antibiotics, synthetic peptides and 
polypeptides, heparins, vitamins, and cell metabolites.
The safety of BtM is based on strict control 
of their starting materials. When assessing the 
risks of contamination of feedstock and starting 
materials, special attention is paid to the risk related 
to contamination with spongiform encephalopathy of 
animals (GPM “Risk of transmission of spongiform 
encephalopathy of animals”) and latent viruses (GPM 
“Viral safety”). Attention should also be paid to starting 
materials in direct contact with process equipment 
or products (such as nutrient media used to simulate 
aseptic filling and lubricants that may come into contact 
with the product).
The biologically-sourced cells and materials 
used in the production must be characterized by and 
meet the requirements of microbiological and viral 
safety under the general pharmacopeia monograph 
“Requirements for cell cultures-substrates for the 
production of biological medicines.”
To prevent unwanted changes in properties as 
a result of repeated subcultures or a large number of 
generations, the production of biological pharmaceutical 
substances and medicines obtained from microorganism 
cultures, cell cultures or propagation in embryos, 
tissues, and organs of animals should be based on 
the main and working seed culture system and (or) 
cell banks. Such a system may not apply to all types of 
high-tech medicines (Table 1).
Table 1: Main conditions for ensuring quality in the production 
of the BtM
The use in the production of only studied, genetically stable production strains of 
microbes and strains-producers characterized and deposited in the official collections 
that have been annually monitored for all biological properties as per the specified 
requirements
At the same time, based on the materials on the study of the genetic stability of the 
production strain, the number of passages of the microbe is limited (GPM “Probiotics,” 
GPM “Bacteriophages,” GPM “Medicines obtained by recombinant DNA methods”)
The use of adequate culture media with high growth properties (raw materials, reactants, 
and reagents used in the production of culture media must have quality certificates)
The use of cell culture, under the WHO recommendations, deposited in the official 
collections and approved for use in production (when culturing cells, the use of native 
human blood serum and penicillin group antibiotics is not allowed) (GPM “Requirements 
for cell cultures-substrates for the production of biological medicines”)
Validation of all stages of the production process. Tests as part of the validation of the 
technological process should include a proper assessment of both the technological 
process of production and each of its stages separately (e.g., the cell cultivation stage, 
the stage of collecting cells grown in culture, the stages of cleaning, mixing, sterilization, 
filling, etc.)
Along with physicochemical and immunochemical methods, the BtM control includes 
biological methods, which are characterized by a higher degree of variability
The methods used for testing should be described as detailed as possible with the 
qualification of reactants, reagents, laboratory equipment, instruments, requirements for 
animals, strains of microbes and cell cultures, etc.
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In the 14th edition of the State Pharmacopeia, 
fifteen general pharmacopeia monographs, eight of which 
had been introduced for the 1st time, were devoted to 
biotechnological medicinal products as objects (Table 2).
Table 2: BtM in the 14th edition of the State Pharmacopeia
Serial number as per the 
14th edition of the SP
General pharmacopeia 
monograph 
List changes as per the 
14th edition of the SP
242 Bacteriophages monograph GPM. 
1.7.1.0002.15
243 Bifid-containing Probiotics 
GPM.1.7.1.0003.15
245 Coli-containing Probiotics 
GPM.1.7.1.0003.15
246 Lactic-containing Probiotics 
GPM.1.7.1.0006.15
247 Recombinant DNA Medicines 
GPM.1.7.1.0007.15
248 Probiotics GPM.1.7.1.0008.15
249 Spore probiotics 
GPM.1.7L.0009.15
250 Biological medicines 
GPM.1.7.1.0010.18
Introduced for the 1st 
time
251 Biotechnological medicines 
GPM.1.7.1.0011.18
Introduced for the 1st 
time
252 Interferons GPM.1.7.1.0012.18 Introduced for the 1st 
time
253 DNA vaccines GPM.1.7.1.0013.18 Introduced for the 1st 
time
254 Monoclonal antibodies for medical 
use GPM.1.7.1.0014.18
Introduced for the 1st 
time
255 Filgrastims GPM.1.7.1.0015.18 Introduced for the 1st 
time
256 Erythropoietin GPM.1.7.1.0016.18 Introduced for the 1st 
time
257 Genetically engineered 
human insulin preparations 
GPM.1.7.1.0017.18
Introduced for the 1st 
time
The pharmacopeial monographs of 
biotechnological preparations in the 14th edition of the 
State Pharmacopeia have the following serial numbers: 
Pirogenal: 593–594, interferons: 586, 615, bacteriophages: 
609–612, 624–631, and probiotics: 603–608, 616–623.
The content analysis of the new general 
pharmacopeia monographs has made it possible to 
determine brief characteristics and identify regulatory 
features for specific groups of BtM.
The general pharmacopeia monograph 
“Interferons” (GPM “Interferons”) applies to the interferons 
obtained through the recombinant DNA technology using 
bacterial or mammalian cells as an expression system.
Interferons belong to the group of cytokines 
and are globular proteins being the broad-spectrum 
multifunctional bioregulators.
The main biological properties of interferons 
are manifested in their antiviral, antiproliferative, and 
immunomodulatory effects.
Three types of interferons are distinguished by 
origin, as follows:
•	 IFNα – leukocyte (produced by leukocytes, 
plasmacytoid dendritic cells, and monocytes/
macrophages)
•	 IFNβ – fibroblast (produced by fibroblasts and 
epithelial cells)
•	 IFN γ – immune (produced by T-lymphocytes 
and natural killer cells).
By the production method, IFNs are divided 
into two groups: Natural (first-generation IFN) 
and recombinant ones obtained using genetically 
engineered technology (second-generation IFN).
Interferon preparations for parenteral 
administration are widely used in health-care practice 
for the treatment of many severe viral diseases, 
including viral hepatitis B, C, D, multiple sclerosis, and 
a wide range of oncological diseases.
Topical preparations (ointments, suppositories, 
drops, etc.) with some nosological forms are capable 
of ensuring the accumulation of large concentrations of 
the medication directly in the lesion in the absence of 
side effects characteristic of parenteral administration 
of high interferon doses. Due to the high concentration, 
in the focus of infection, a pronounced local antiviral 
and immunostimulating effect is achieved with a slight 
systemic absorption.
The quality indicators and requirements for 
them that depend on the medication form are regulated 
by the general pharmacopeia monographs on the 
relevant dosage form: GPM “Parenteral dosage forms,” 
GPM “Aerosols and sprays,” GPM “Opthalmic dosage 
forms,” GPM “Ointments,” etc.
It is important to note that the GPM “Interferons” 
does not apply to the modified (pegylated [obtained by 
attaching polyethylene glycol]) interferons.
The list of vital and essential drugs for 2019 
includes interferons by groups L03A immunostimulants, 
L03AB interferons: Interferon-alpha, interferon beta-1a, 
interferon beta-1b, Interferon-gamma, peginterferon 
alpha-2a, peginterferon alfa-2b, peginterferon beta-1a, 
and peginterferon alfa-2b.
Interferon alfa, peginterferon alfa-2a, and 
peginterferon alfa-2b are included in the list of medicines 
prescribed by the decision of the medical commissions 
of medical organizations.
To provide medicines to the patients with 
multiple sclerosis that is one of the 12 high-cost 
nosologies, the relevant restrictive list provides for the 
purchase of the following medicines: Interferon-beta-1a, 
interferon beta-lb, and peginterferon beta-1a.
The general pharmacopeia monograph 
“Monoclonal Antibodies” defines that monoclonal 
antibodies for medical use are immunoglobulins or 
fragments of immunoglobulins characterized by strict 
antigenic specificity and produced by a single cell 
clone. Monoclonal antibodies can be conjugated to 
other substances, including radioactive labels.
Monoclonal antibodies are produced using 
recombinant DNA and hybridoma technology and can 
also be produced using other technologies.
Types of monoclonal antibodies are as follows:
Chimeric monoclonal antibodies, in which the 
variable domains of the heavy and light chains of a 
human immunoglobulin are replaced by the relevant 
immunoglobulin domains of a different species origin 
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(mainly rodents — mice or rats) with the required 
antigenic specificity.
Humanized monoclonal antibodies, in which 
three short hypervariable sequences of the variable 
domains of each immunoglobulin chain (regions 
determining the complementary antigen-binding – 
CDRs), are of murine (or other) origin and are integrated 
into the structure of the variable domains of a human 
immunoglobulin. Other changes in the hypervariable 
sequence may be introduced to improve antigen 
binding.
Recombinant human antibodies, in which the 
variable domains of the heavy and light chains of a 
human immunoglobulin are combined with a constant 
region of a human immunoglobulin.
The production of monoclonal antibodies is 
based on a system of cell banks (the Main Cell Bank 
and the Working Cell Bank) derived from cloned cells. 
The biologically-sourced cells and materials used in the 
manufacturing process should be characterized under 
the requirements outlined in the GPM “Requirements for 
cell cultures – substrates for the production of biological 
medicines,” and the GPM “Medicines obtained by 
recombinant DNA methods.”
The stages of the production process for 
monoclonal antibodies should be characterized as 
per the requirements outlined in the GPM “Medicines 
obtained by recombinant DNA methods.” If different 
monoclonal antibodies are produced at the same 
production site, the authentication method must 
uniquely identify each monoclonal body produced in the 
presence of the others.
Monoclonal antibody medicines are available 
in the following parenteral dosage forms:
•	 Injection and infusion forms (solution for 
injection, solution for infusion, and solution for 
subcutaneous administration)
•	 Concentrates for the injection and infusion 
forms (concentrate for the solution for infusion)
•	 Solid dosage forms intended for the injection 
and infusion dosage forms (lyophilizate for 
solution for infusion, etc.).
Lyophilizate can be supplied complete with a 
solvent approved for medical use, whereas the solvent 
should not affect the quality of the medicine.
It is important to note that the requirements 
of the GPM “Monoclonal Antibodies” do not apply to 
monoclonal antibodies that are used as reagents in the 
production of other medicines, monoclonal antibodies 
obtained in vivo (in the form of ascites), and monoclonal 
antibodies for in vitro diagnostic purposes.
The list of vital and essential drugs for 2019 
includes 36 names of monoclonal antibody preparations, 
19 of which are also included in the list of preferential 
provision drugs, which are prescribed by the decision of 
the medical commission (Table 3).
Table 3: Monoclonal antibodies in the list of vital and essential 
drugs for 2019
C10AX Other lipid-lowering 
medicines
Alirocumab* Solution for subcutaneous 
administration
Evolocumab Solution for subcutaneous 
administration
J06BB Specific 
immunoglobulins
Palivizumab Lyophilizate for solution for 
intramuscular administration
L01XC Monoclonal antibodies Atezolizumab Infusion solution concentrate
Bevacizumab* Infusion solution concentrate
Blinatumomab 
(New 2019)
Powder for the infusion solution 
concentrate
Brentuximab 
vedotin
Lyophilizate for the infusion 
solution concentrate
Daratumumab Infusion solution concentrate
Ipilimumab (New 
2019) 
Infusion solution concentrate
Nivolumab Infusion solution concentrate
Obinutuzumab Infusion solution concentrate
Panitumumab* Infusion solution concentrate
Pembrolizumab Infusion solution concentrate
Pertuzumab* Infusion solution concentrate
Rituximab* Infusion solution concentrate 
solution for subcutaneous 
administration
Trastuzumab* Lyophilizate for the infusion 
solution concentrate infusion 
solution lyophilizate solution for 
subcutaneous administration
Trastuzumab 
emtansine
Lyophilizate for the infusion 
solution concentrate
Cetuximab* Infusion solution
L04AA Selective 
immunosuppressants
Alemtuzumab Infusion solution concentrate
Belimumab 
(New 2019)
Lyophilizate for the infusion 
solution concentrate
Vedolizumab* Lyophilizate for the infusion 
solution concentrate
Natalizumab Infusion solution concentrate
Ocrelizumab 
(New 2019)
Infusion solution concentrate
Eculizumab Infusion solution concentrate
L04AB Tumor necrosis 
factor inhibitors alpha 
(TNF-alpha)
Adalimumab Solution for subcutaneous 
administration
Golimumab* Solution for subcutaneous 
administration
Infliximab* Infusion solution lyophilizate for 
the infusion solution concentrate
Certolizumab 
pégol*
Solution for subcutaneous 
administration
L04AC Interleukin inhibitors Basiliximab Lyophilizate for solution for 
intravenous administration
Canakinumab* Lyophilizate for solution for 
subcutaneous administration
Secukinumab* Lyophilizate for solution for 
subcutaneous administration 
solution for subcutaneous 
administration
Tocilizumab* Infusion solution concentrate 
solution for subcutaneous 
administration
Ustekinumab* Solution for subcutaneous 
administration
M05BX Other medicines that 
affect bone structure 
and mineralization
Denosumab* Solution for subcutaneous 
administration
R03DX Other systemic drugs 
for the treatment of 
obstructive airways 
diseases
Omalizumab* Lyophilizate for solution for 
subcutaneous administration 
solution for subcutaneous 
administration
S01LA Medicines preventing 
vascular neoplasm
Ranibizumab Solution for intraocular 
administration
*The medicines also included in the list of preferential provision drugs, which are prescribed by the decision 
of the medical commission.
Monoclonal antibodies are used to treat 
patients with high-cost nosologies. Rituximab is 
included in the list of medicines provided to patients 
with malignant neoplasms of lymphoid, hematopoietic, 
and related tissues. Natalizumab is included in the LIST 
of medicines for patients with multiple sclerosis.
For patients with the hemolytic-uremic 
syndrome, one of five additional high-cost nosologies, 
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Eculizumab, is purchased for the 1st time. For patients 
with juvenile arthritis with systemic onset, also 
an additional high-cost nosology, the monoclonal 
antibodies purchased are tocilizumab, adalimumab, 
and canakinumab.
The general pharmacopeia monograph 
“Filgrastims” includes the requirements for recombinant 
filgrastim (granulocyte-colony stimulating factor) 
obtained through the recombinant DNA technology 
using bacterial cells as an expression system.
Filgrastim preparations stimulate the 
proliferation and differentiation of neutrophils and 
release thereof from the bone marrow into the blood.
Filgrastim-based medicines are available in 
forms for parenteral use: injection (for intravenous and 
subcutaneous administration) and infusions.
It is important to note that the GPM 
“Filgrastims” does not apply to the modified filgrastims 
(pegylated filgrastims) (pegfilgrastim, lipegfilgrastim, 
and empegfilgrastim).
The list of vital and essential drugs for 2019 
includes L03AA colony-stimulating factors (L03A 
Immunostimulants): Filgrastim (solution for intravenous 
and subcutaneous administration; solution for 
subcutaneous administration) and empegfilgrastim 
(solution for subcutaneous administration).
The general pharmacopeia monograph 
“Erythropoietin” includes the requirements for the 
erythropoietin (epoetins) obtained through the 
recombinant DNA technology using mammalian cells 
as an expression system.
Erythropoietin specifically stimulates the 
proliferation and differentiation of erythrocyte cells. 
Erythropoietin preparations are used for the prevention 
and treatment of anemia of various origins.
Recombinant erythropoietin-based drugs are 
available in the form for the parenteral use: Injection 
solution and lyophilizate. Lyophilizate can be supplied 
complete with a solvent approved for medical use.
It is important to note that the GPM 
“Erythropoietin” does not extend to the erythropoietin 
with a modified amino acid sequence (darbepoetin) and 
modified erythropoietin (pegylated erythropoietin).
In the list of vital and essential drugs for 
2019, erythropoietin is included in the group B03X 
– Other antianemic drugs: Darbepoetin alpha, 
methoxypolyethylene glycol-epoetin beta, epoetin 
alpha, and epoetin beta.
The list of preferential provision drugs 
includes all four positions of erythropoietin in the 
indicated dosage forms, whereas darbepoetin alpha 
and methoxypolyethylene glycol-epoetin beta are 
prescribed by the decision of the medical committee.
The general pharmacopeia monograph “DNA 
Vaccines” defines that these are the drugs whose 
active substance is purified recombinant – plasmid/viral 
vectors obtained using recombinant DNA technology, 
containing one or more DNA sequences capable 
of inducing and/or activating an immune response 
to a pathogen or non-infectious disease. Typically, 
these plasmid/viral vectors contain DNA sequences 
necessary for selection and replication in bacterial 
or mammalian cells. In addition, they contain a 
eukaryotic promoter, an enhancer, and a sequence for 
termination/-polyadenylation of transcription to activate 
gene expression in vaccine recipients, and may also 
contain immunomodulating elements.
DNA vaccines can be bacterial cells with a 
plasmid or a single vector, which is usually a viral vector.
Biological pharmaceutical substances of 
these preparations are obtained using cultures of 
characterized cells, which may be bacteria, mammalian 
cells (in which case they are called a substrate), etc.
The requirements for a specific biological 
pharmaceutical substance and medicines based on 
them should be set out in the relevant pharmacopeial 
monographs or regulatory documents.
It is important to note that the GPM “DNA 
vaccines” do not apply to the vaccines based on live 
viral vector and to gene therapy drugs.
The examples of the DNA vaccines registered 
in Russia are: Hepatitis B recombinant vaccine, human 
papillomavirus quadrivalent recombinant vaccine, 
recombinant adsorbed human papillomavirus vaccine 
containing AS04 adjuvant, and bivalent.
The general pharmacopeia monograph 
“Genetically engineered human insulin preparations” 
applies to the genetically-engineered human 
insulin preparations obtained using recombinant 
DNA technology from genetically stable and safe 
microorganisms.
Genetic engineering drugs of human insulin 
are available in parenteral dosage forms.
It is important to note that the requirements 
of the GPM “Genetically engineered human insulin 
preparations” do not apply to bovine insulin, porcine 
insulin, and semi-synthetic insulin.
The list of vital and essential drugs for 2019 
contains the following genetically engineered human 
insulin preparations for the treatment of diabetes 
mellitus:
•	 Short-acting insulins and their analogs for 
injection (A10AB): Insulin aspart, Insulin 
glulisine, insulin lispro, soluble insulin
•	 Medium-duration action insulins and their 
analogs for injection (A10AB): (Human 
genetically engineered) insulin-isofan
•	 Medium-duration or long-acting insulins and 
their analogs in combination with short-acting 
insulin for injection (A10AD): Two-phase insulin 
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aspart, insulin degludec + insulin aspart, two-
phase insulin lispro, and insulin two-phase 
(human genetic engineering)
•	 Long-acting insulins and their analogs for 
injection (A10AE): Insulin glargine, insulin 
degludec, and insulin detemir.
All the above insulin items are also included 
in the list of preferential provision drugs, whereas 
the insulin degludec + insulin aspart and insulin 
degludec are prescribed by the decision of the medical 
commission.
Discussion
As part of the work in 2019 to review the 
lists of medicines according to the results of the 
examination, the Commission of the Ministry of Health 
of Russia has proposed new BtM to be included in the 
list of vital and essential drugs for 2020, of which new 
monoclonal antibodies are the most significant ones 
for the treatment of a number of diseases, namely, 
mepolizumab, İxekizumab, dupilumab, ramucirumab, 
benralizumab, reslizumab, elotuzumab, sarilumab, and 
netakimab [11].
Conclusion
The subjects of BtM circulation in the Russian 
pharmaceutical market must take into account 
the requirements of the 14th edition of the State 
Pharmacopeia at all circulation stages.
The regulatory documents for the registered 
medicines and their constituent pharmaceutical 
substances, as well as the pharmaceutical substances 
produced for sale and included in the state register of 
medicines for medical use, must be brought into line 
with the approved general pharmacopeia monographs 
and the monographs until January 1, 2022.
BtM occupies an important place in the list of 
vital and essential drugs and other restrictive lists.
It must be expected that new BtM, including 
monoclonal antibodies, would be reviewed and included 
in the relevant restrictive lists for 2020.
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